Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor

Craigavon, N.I., UK, Lausanne, Switzerland, 20 June 2017 Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Debiopharm International SA, a Switzerland based speciality pharma company, today announced a collaboration to pursue the development of Almac Discovery’s Wee-1 kinase inhibitor programme.

Under the terms of the license agreement, Almac Discovery has granted exclusive global rights to its Wee-1 patent families and related subject matter expertise to Debiopharm International SA. Almac Discovery is eligible to receive an upfront payment with further development and commercial milestone payments in addition to receiving royalties from Debiopharm.

The area of DNA damage response and cell cycle regulation has seen notable activity from the pharmaceutical industry recently, including some high profile drug approvals for cell cycle kinase inhibitors. Many cancer treatments such as radiation, antimetabolites, alkylating agents, DNA topoisomerase inhibitors and platinum compounds damage DNA in cells. The cellular response is to arrest the cell cycle temporarily to allow for DNA repair, hence reducing the efficacy of chemotherapy.

The Wee-1 kinase is a key regulator of a number of cell cycle checkpoints and inhibition of Wee1 can force arrested cells through the cell cycle leading to cell death. The Almac Discovery Wee-1 inhibitors exhibit good drug-like properties, high potency, excellent selectivity and demonstrate potent anti-proliferative activity in vitro and in vivo, both as single agents and in combination with genotoxics, in several cancer models.

“We are thrilled to pursue the outstanding work of Almac Discovery on this promising target.” said Dr. Bertrand Ducrey, CEO of Debiopharm International SA, who added “Almac Discovery’s compelling expertise in medicinal chemistry and drug discovery is very complementary with Debiopharm business model and we look forward to developing these compounds to offer an innovative treatment for patients with high medical need.”

Dr Stephen Barr, Managing Director & President, Almac Discovery commented “We are extremely pleased to announce this agreement with Debiopharm who have proven expertise and an impressive track record of developing drug candidates. The professionalism, dedication and commitment of their team is aligned perfectly with our own core values making them the number one choice to develop our Wee-1 inhibitor. Agreements of this nature enable both companies to continue to strive to improve human health worldwide and we look forward to working with them.”

 

About Almac Discovery

Almac Discovery is a research driven oncology company dedicated to the discovery and development of novel and innovative approaches to the treatment of cancer. Almac Discovery focuses on the discovery to preclinical stage seeking to licence programmes early with a pharmaceutical partner for further development.

For more information, please visit www.almacgroup.com/discovery or e-mail media@almacgroup.com.

 

About Debiopharm International SA

Part of Debiopharm Group™ – a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management – Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.

For more information, please visit www.debiopharm.com. We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews

Souderton, US, June 19, 2017 – Almac Group, the global contract pharmaceutical development and manufacturing organisation, is delighted to have received recognition as a US-Ireland Top 50 Company for its commitment to building prosperity through business and job creation.

The Irish Echo Newspaper’s 10th Annual Awards Luncheon highlights companies who exhibit dedication to strengthening international trade between the US and Northern Ireland. The luncheon emphasises a commitment to future progress and prosperity between the citizens of New York, NY, US and Belfast, Northern Ireland, UK, while celebrating a shared history and past.

Read More

Father’s Day: 10 business and life lessons I learned from my dad

When my father started his business in 1975 with $16,000 in his savings account, he was 27 and scared – yet determined to listen to a loud inner voice calling him to help others. Forty-two years later, having grown BAYADA Home Health Care to a $1 billion organization with 25,000 employees serving more than 100,000 people each year, my father announced an innovative and unchartered path to succession. Instead of taking his private, family-owned company public, selling it to private equity or passing it down to my siblings and me, my father decided to put mission over money by transitioning the business into a nonprofit that he will steward as chairman beginning August 17 – his 70th birthday.

To read more, please click HERE.

Friday 16th June 2017, Crumlin, Co.Antrim: Randox named in US-Ireland Top 50 Companies at New York New Belfast conference

Global healthcare company Randox, which is headquartered in Co. Antrim and has key R&D, engineering and manufacturing facilities in both Co. Antrim and Co. Donegal, has been named in The US-Ireland Top 50 Companies, to be announced today, Friday 16 June, at the New York/New Belfast conference in Manhattan.

Read More

Welcome new Irish Chamber members!
Be sure to look out for new members at upcoming events. They will have maroon ribbons on their name tags.

Individual Members

Janice K. Marini, Thomas Jefferson University
James Harbeson, Bank of America
Thomas Morrissey, Univest Insurance, Inc.
– William Leahy, Littler Mendelson
Colin Burke, Merrill Lynch, Pierce, Fenner & Smith Inc.
R. Brian Neary, Newmark Grubb Knight Frank
Brian Cleary, McKenna’s Irish Kitchen & Market
Robert Rae, Columbus Business Partners
Jill Baxter, MSE, ASQ-CQE, Exponent, Inc.
Pat Toner, Structure Tone LLC
Michael McCourt, BNY Mellon
Robert Rae, Columbus Business Partners
Cheryl O’Brien, C. O’Brien Architects / Berkshire Hathaway Realty
Patricia Buchanan, PMB Marketing LLC
Charles Brennan, Brennan Sales Institute
– Jim McCormick, Boenning & Scattergood, Inc.
– Kevin Sweeney, Chamberlain, Hrdlicka, White, Williams & Aughtry
Matthew Blatz, PCS
Rick Freeth, Tactix Real Estate Advisors
Patrick McGowan, Fidato Partners
James Kilcur, Jr, Bank of America


Mid-Size Firm Members

– U.S. Trust, William Meagher, Michael P. Terry
The Graham Company, Andrew Corrigan, Kevin Funston
– Diati Staffing, LLC, Keegan McCool, Dan Smith
– Wiley Group, Don Riley, Shannon Breuer, Timothy Hewitt
 Spark Therapeutics, Inc., John Furey
– Commercial Utility Consultants, Joseph P. McGillian, Andrew McGillian
WBEB 101.1 More FM, Betsy Oliphant, Kerry Mulvey, Jim Loftus
Irish American Films, Shawn Swords, Bob Charger


Large Corporate Members

Palm Beach Kennel Club
Penn Medicine Abramson Cancer Center
Tague Lumber


Ambassador Club Members

– John J. Rooney Family
Beneficial Bank
PixarBio
KYW Newsradio


Thank you to Renewing Members

Individual Members

– Rich Meehan, Meehan Wealth Advisors
– Lisa Maloney, Berkadia
– Kathleen McGarvey, Firstrust Bank
– Michael Krach, Signature Advisors Inc./ACKK Inc.
– Daniel Heenan, RBC Wealth Management
– Joseph Purcell, EisenerAmper LLP
– Siobhan Reardon, The Free Library of Philadelphia
– James R. Malone, Jr., Post & Schell, P.C.
– Mike Mamula, CSS
– Jack Kelly, KG Associates
– Mike Riley, EthoSource LLC
– Bill Watkinson, Watkinson Capital Advisors LLC

Mid-Size Firm Members
– TMC Consulting, Tom McCool
– Teleflex, Liam Kelly

Corporate Members
– Údarás na Gaeltachta
– Beneficial Bank
– PixarBio
– KYW Newsradio
– Akin Gump
– Conrad O’Brien, PC
– KPMG
– ICON Clinical Research
– Mazars USA LLP
– Murtagh Brothers
– Aramark
– Penn Mutual Life Insurance Company
– Villanova University
– Windsor Financial Group
– SmartInvest Ventures, LLC
– Stradley Ronon
– Volpe & Koenig

Almac Group Awarded U.S. Patents for Ground-breaking “DDRD” Assay

Craigavon, N.I., 13 June 2017 – Almac Group’s Diagnostics business unit announced today it has been granted U.S. patent protection for its DNA Damage Response Deficiency (DDRD) assay. The U.S. Patent and Trademark Office (USPTO) issued U.S. Patent Numbers 9,670,547 & 9,677,140, each entitled, “Molecular Diagnostic Test for Cancer”, effective until 2031. This adds to the patent protection already granted in China, Singapore, Australia, New Zealand and South Africa for this assay.

Read More